Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,565 shares of the specialty pharmaceutical company’s stock after selling 554 shares during the period. Amalgamated Bank’s holdings in Supernus Pharmaceuticals were worth $510,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of SUPN. Bank of New York Mellon Corp raised its position in shares of Supernus Pharmaceuticals by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock worth $14,449,000 after purchasing an additional 27,134 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Atria Investments Inc acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $288,000. Proficio Capital Partners LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $408,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $6,847,000.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, June 21st.

Supernus Pharmaceuticals Trading Up 1.4%

SUPN stock opened at $33.14 on Friday. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 29.86 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 12 month low of $27.05 and a 12 month high of $40.28. The firm has a 50-day moving average of $32.25 and a two-hundred day moving average of $33.78.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.